Novel Spectacle Lenses for Near-sightedness
(CHERRY Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how new spectacle lenses might help manage near-sightedness (difficulty seeing far away). Researchers focus on how changes in the thickness of the choroid (a layer of blood vessels behind the retina) affect vision over time. Participants already in the CPRO-1802-001 study who have signed the necessary consent forms may be suitable candidates to join.
As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research in vision care.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that these novel spectacle lenses are safe for near-sightedness?
Research has shown that new glasses for nearsightedness (myopia) are safe for use. Studies have found them comfortable for extended wear. In one study, the glasses proved safe and effective for children with myopia over a year. Another study demonstrated their safety and ability to slow myopia progression over four years. These findings suggest that the glasses are generally safe, with no major side effects reported.12345
Why are researchers excited about this trial?
Unlike traditional glasses that simply correct vision by refocusing light onto the retina, the novel spectacle lenses for near-sightedness are designed to alter the way light is focused in the peripheral retina. This approach aims to slow down the progression of near-sightedness, or myopia, by addressing its underlying causes rather than just its symptoms. Researchers are excited about these lenses because they could potentially reduce the need for stronger prescriptions over time, offering a more sustainable and long-term solution for managing myopia.
What evidence suggests that these novel spectacle lenses are effective for near-sightedness?
Research has shown that new types of glasses can help slow the progression of near-sightedness (myopia). Studies have found that these special lenses significantly reduce both the elongation of the eye and the deterioration of vision compared to regular glasses. For instance, some lenses reduced myopia progression by 47%–69% in certain groups. One study found that these lenses slowed both eye growth and vision changes over a year. This evidence suggests that the lenses tested in this trial effectively manage and control myopia.678910
Who Is on the Research Team?
Lyndon Jones, PhD, FCoptom
Principal Investigator
Centre for Ocular Research & Education, Canada
Jill Woods, BSc, MCOptom
Principal Investigator
Centre for Ocular Research & Education, Canada
Are You a Good Fit for This Trial?
This trial is for individuals already enrolled in the CPRO-1802-001 study who have near-sightedness, including degenerative or progressive myopia. Participants must be minors who've given their assent and whose parents or guardians have signed a consent letter. Those with temporary health issues affecting the eyes like colds, allergies, or fatigue cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants wear novel spectacle lenses designed to inhibit myopia progression
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Novel Spectacle Lens
Find a Clinic Near You
Who Is Running the Clinical Trial?
SightGlass Vision, Inc.
Lead Sponsor
University of Waterloo
Collaborator